1. Home
  2. CRBP vs SANG Comparison

CRBP vs SANG Comparison

Compare CRBP & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$9.69

Market Cap

202.6M

Sector

Health Care

ML Signal

HOLD

Logo Sangoma Technologies Corporation

SANG

Sangoma Technologies Corporation

N/A

Current Price

$5.37

Market Cap

170.0M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
SANG
Founded
2009
1984
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
202.6M
170.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CRBP
SANG
Price
$9.69
$5.37
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$50.29
N/A
AVG Volume (30 Days)
513.0K
4.7K
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$227,360,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$100.00
$4.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.64
$4.08
52 Week High
$20.56
$7.99

Technical Indicators

Market Signals
Indicator
CRBP
SANG
Relative Strength Index (RSI) 34.73 56.96
Support Level $9.44 $5.07
Resistance Level $11.64 $5.42
Average True Range (ATR) 0.74 0.13
MACD -0.02 0.03
Stochastic Oscillator 12.16 91.26

Price Performance

Historical Comparison
CRBP
SANG

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

Share on Social Networks: